# Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients

> **NCT04531592** · PHASE2 · WITHDRAWN · sponsor: **Westat**

## Conditions studied

- Acute Kidney Injury
- Ischemia Reperfusion Injury

## Interventions

- **DRUG:** Valproic acid
- **DRUG:** Isotonic saline solution

## Key facts

- **NCT ID:** NCT04531592
- **Lead sponsor:** Westat
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study terminated by the Sponsor
- **Last updated:** 2021-10-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04531592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04531592, "Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04531592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*